MorphoSys granted GlaxoSmithKline exclusive, worldwide rights to develop and commercialize MOR103

MorphoSys AG

Germany / Mid-Cap Biopharma ($1-$50 billion)

$1,188.8m on 06/07/2013 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

GlaxoSmithKline plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced